UBS recently reaffirmed its Buy rating on Veracyte after the company’s fourth-quarter testing revenue came in ahead of expectations and management issued 2026 testing revenue projections that were higher than consensus estimates.
The analyst commentary also emphasized that potential contributions from Veracyte’s newer products are not yet fully reflected in current revenue projections, suggesting investors may be underappreciating the company’s broader testing pipeline.
We’ll now examine how UBS’s confidence in Veracyte’s stronger-than-expected testing revenue and 2026 outlook could influence the company’s investment narrative.
Find 54 companies with promising cash flow potential yet trading below their fair value.
To own Veracyte, you generally need to believe its genomic tests can keep expanding beyond core products like Decipher and Afirma, while maintaining healthy margins. UBS’s reaffirmed rating, tied to stronger-than-expected Q4 testing revenue and a higher 2026 testing outlook, supports that thesis but does not eliminate the key near term risk that reimbursement or guideline decisions could slow adoption and compress economics.
The most relevant recent update is Veracyte’s 2026 revenue guidance of US$570 million to US$582 million, given on 11 January 2026. That outlook provides a concrete yardstick against UBS’s view that current projections may still understate contributions from newer offerings such as the MRD platform and expanded Decipher indications, and it anchors how investors might think about timing and scale of the next leg of test menu driven growth.
Yet, against this optimism, investors should still pay close attention to the risk that reimbursement pressures could materially affect Veracyte’s revenue concentration and pricing power…
Read the full narrative on Veracyte (it’s free!)
Veracyte’s narrative projects $629.2 million revenue and $121.9 million earnings by 2028.
Uncover how Veracyte’s forecasts yield a $47.50 fair value, a 33% upside to its current price.
VCYT 1-Year Stock Price Chart
Some of the lowest ranked analysts were already assuming slower growth, with revenue only reaching about US$616.3 million and earnings around US$50.8 million by 2028, so UBS’s upbeat reaction to the stronger testing outlook may or may not shift that more cautious view, and it is worth comparing these different scenarios before deciding which future you find more credible.
Explore 5 other fair value estimates on Veracyte – why the stock might be worth 32% less than the current price!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VCYT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com